These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31249232)

  • 1. Management of phosphate abnormalities in hemodialysis patients: Findings from Malaysia.
    Mohamed Koya SNM
    Saudi J Kidney Dis Transpl; 2019; 30(3):670-677. PubMed ID: 31249232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Hypo- and Hyperphosphatemia in an Intensive Care Unit Cohort.
    Broman M; Wilsson AMJ; Hansson F; Klarin B
    Anesth Analg; 2017 Jun; 124(6):1897-1905. PubMed ID: 28525508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
    Wald R; Rabbat CG; Girard L; Garg AX; Tennankore K; Tyrwhitt J; Smyth A; Rathe-Skafel A; Gao P; Mazzetti A; Bosch J; Yan AT; Parfrey P; Manns BJ; Walsh M
    Clin J Am Soc Nephrol; 2017 Jun; 12(6):965-973. PubMed ID: 28550080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
    Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
    J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
    Ramos R; Chazot C; Ferreira A; Di Benedetto A; Gurevich K; Feuersenger A; Wolf M; Arens HJ; Walpen S; Stuard S
    BMC Nephrol; 2020 Dec; 21(1):530. PubMed ID: 33287733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
    Galassi A; Cupisti A; Santoro A; Cozzolino M
    J Nephrol; 2015 Aug; 28(4):415-29. PubMed ID: 25245472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypophosphatemia: nutritional status, body composition, and mortality in hemodialysis patients.
    Garagarza C; Valente A; Caetano C; Oliveira T; Ponce P; Silva AP
    Int Urol Nephrol; 2017 Jul; 49(7):1243-1250. PubMed ID: 28265965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphate Kinetics During Weekly Cycle of Hemodialysis Sessions: Application of Mathematical Modeling.
    Debowska M; Poleszczuk J; Wojcik-Zaluska A; Ksiazek A; Zaluska W
    Artif Organs; 2015 Dec; 39(12):1005-14. PubMed ID: 25994493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphate binders usage, patients knowledge, and adherence. A cross-sectional study in 4 centers at Qassim, Saudi Arabia.
    Aleidi AM; Alayed NJ; Alduraibi HM; Alqassimi NS; Ismail AA
    Saudi Med J; 2020 Oct; 41(10):1076-1082. PubMed ID: 33026048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients.
    Chan MW; Cheah HM; Mohd Padzil MB
    Int J Clin Pharm; 2019 Oct; 41(5):1282-1289. PubMed ID: 31302884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and baseline characteristics of the LANDMARK study.
    Ogata H; Fukagawa M; Hirakata H; Kaneda H; Kagimura T; Akizawa T;
    Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders.
    Sherman RA
    Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disorders of phosphate metabolism.
    Leung J; Crook M
    J Clin Pathol; 2019 Nov; 72(11):741-747. PubMed ID: 31467040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between phosphate binders prescription, illness perception, and depression in hemodialysis patients.
    Mohamed Koya SNMV; Zulkepli NA
    Saudi J Kidney Dis Transpl; 2018; 29(4):828-836. PubMed ID: 30152419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.